NovaBay Pharmaceuticals – Consensus Indicates Potential 119.2% Upside

Broker Ratings

NovaBay Pharmaceuticals with ticker code (NBY) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The target price ranges between 3.5 and 1.75 with a mean TP of 2.63. Given that the stocks previous close was at 1.2 this now indicates there is a potential upside of 119.2%. The 50 day moving average now sits at 0.91 and the 200 day moving average is 0.81. The market capitalisation for the company is $48m. Find out more information at:

NovaBay Pharmaceuticals, a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals and changed its name to NovaBay Pharmaceuticals in February 2007. NovaBay Pharmaceuticals was incorporated in 2000 and is headquartered in Emeryville, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits
You might also enjoy reading  NovaBay Pharmaceuticals - Consensus Indicates Potential 328.6% Upside

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index